Cipla vs Apollohosp Q1 FY26

Cipla reported Q1 FY26 revenue of INR 6,957 crore (+4% YoY) with EBITDA margin of 25.6% (flat YoY) and PAT of INR 1,298 crore (+10.2% YoY). India business crossed INR 3,000 crore for the first time in a Q1, growing 6% YoY, but branded prescription growth was muted due to slow respiratory/acute market (4-5% growth) and sales force realignment. US revenue was $226 million, impacted by price erosion in a large product, but new launches (NanoPaclitaxel, Nilotinib) and Lanreotide recovery provide cushion. Management maintained FY26 EBITDA margin guidance of 23.5%-24.5%. Key risks include Revlimid revenue phasing uncertainty and slower India branded growth recovery.

Guidance read

FY26 EBITDA margin guidance maintained at 23.5%-24.5%: Management reiterated the full-year EBITDA margin range despite Q1 margin of 25.6% being above the range, citing potential Revlimid phasing and R&D investments. US revenue target of ~$1 billion by FY27: CEO stated pipeline (including respiratory launches like generic Symbicort) should get US revenue closer to or surpass $1 billion by FY27. India branded business to grow in line with IPM in next three quarters: COO expressed confidence that India branded prescription business will grow at industry rates for the remaining quarters of FY26. Biosimilar launch in US expected in Q2 FY26: Company signed agreement to launch first biosimilar in US (supportive care in oncology) via partnership; own biosimilars expected by 2029-30.

Risk read

Key risks include Revlimid revenue phasing uncertainty — Management could not provide precise timing of Revlimid revenue decline, which may impact quarterly US revenue and margins.; Slower India branded prescription growth — India branded business grew only ~3% (ex-consumer), impacted by slow respiratory/acute market and sales force realignment; recovery may take longer.; Indore facility reinspection risk — Indore facility is due for US FDA reinspection within the next year; any adverse outcome could disrupt US supplies.; GLP-1 market competition and execution — Management acknowledged GLP-1 market will be crowded; Cipla's strategy is still evolving and may face challenges in capturing share..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.

Apollo Hospitals delivered a strong Q1 FY26 with consolidated revenue of INR 5,842 crore (+15% YoY) and PAT of INR 433 crore (+42% YoY). Healthcare Services revenue grew 11% to INR 2,935 crore, with EBITDA margins at 24.5% (+88bps YoY). Apollo HealthCo revenue rose 19% to INR 2,472 crore, driven by pharmacy distribution and narrowing digital losses (EBITDA loss of INR 73 crore vs INR 116 crore last year). The company added 700 beds in the pipeline and expects to operationalize them in FY26. Management guided for 13-14% organic hospital growth and Apollo 24/7 breakeven by Q4 FY26. Risk: New hospital ramp-up may cause a ~100bps margin dip in the near term.

Guidance read

Apollo 24/7 breakeven by Q4 FY26: Digital business expected to achieve EBITDA breakeven by end of fiscal year, with GMV run-rate of INR 800-900 crore. 700 beds operational in FY26: New hospitals in Delhi, Pune, Bangalore, and Kolkata to add 700 beds during FY26. HealthCo+Keimed revenue run-rate of INR 25,000 crore by FY27: Combined entity targeting INR 25,000 crore revenue with 7% EBITDA margin by end of FY27. Hospital EBITDA margin target of 25%+: Existing hospital margins expected to expand to 25%+ before new bed dilution of ~100bps.

Risk read

Key risks include New hospital ramp-up margin dilution — Management expects ~100bps margin dip from new hospitals, with total EBITDA impact of INR 100-150 crore over two years.; International patient recovery uncertainty — Bangladesh patient flow remains below pre-crisis levels; recovery timeline is uncertain despite new markets like Iraq.; Quick commerce competition in pharmacy — Aggressive entry of quick commerce players into prescription medicines could pressure margins and customer acquisition costs..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.